Literature DB >> 16177862

Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion.

Rami Younan1, Shigeki Kusamura, Dario Baratti, Grazia Daniela Oliva, Pasqualina Costanzo, Myriam Favaro, Cecilia Gavazzi, Marcello Deraco.   

Abstract

BACKGROUND: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP) are increasingly used in the management of carcinomatosis of various sites of origin. We analyzed the risk factors for bowel complications with primary anastomoses and the closed technique for IPHP.
METHODS: From 1995 to 2004, 203 consecutive procedures were performed at the National Cancer Institute of Milan. We retrospectively analyzed this series of patients. Treated pathologies included peritoneal mesothelioma; pseudomyxoma peritonei; colorectal, ovarian, or gastric carcinomatosis; and abdominal sarcomatosis. All digestive anastomoses were performed before the IPHP. Only one defunctioning stoma was used.
RESULTS: We found a bowel complication rate of 10.8%. The bowel complications:anastomoses ratio was 11.3%. On univariate analysis we found a statistically significant association between bowel complications and the following variables: sex, previous systemic chemotherapy status, number of anastomoses ( fewer than two vs. two or more), duration of the procedure (<8.7 vs. >or=8.7 hours), and extent of cytoreduction. After multivariate analysis, male sex (odds ratio [OR], 4.2), no previous systemic chemotherapy (OR, 3.5), and duration of the procedure >or=8.7 hours (OR, 6.3) were considered independent risk factors for bowel complications.
CONCLUSIONS: Bowel complications are not increased when primary unprotected anastomoses are performed during peritonectomy and IPHP when the closed technique is used. Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177862     DOI: 10.1245/ASO.2005.11.030

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  [Scoring systems for clinical staging of peritoneal carcinomatosis. A critical analysis].

Authors:  J Jähne; S Kübler
Journal:  Chirurg       Date:  2007-12       Impact factor: 0.955

2.  Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.

Authors:  P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

3.  The use of carbon dioxide insufflation to facilitate identification of intestinal injuries in patients undergoing cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  M A Kozman; O M Fisher; S J Valle; N Alzahrani; D L Morris
Journal:  Tech Coloproctol       Date:  2017-06-14       Impact factor: 3.781

4.  Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Dario Baratti; Shigeki Kusamura; Barbara Laterza; Maria Rosaria Balestra; Marcello Deraco
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 5.  Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin.

Authors:  F Losa; P Barrios; R Salazar; J Torres-Melero; M Benavides; T Massuti; I Ramos; E Aranda
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

6.  Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC).

Authors:  Konstantinos Chouliaras; Edward A Levine; Nora Fino; Perry Shen; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2016-12-19       Impact factor: 5.344

7.  Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity.

Authors:  Franco Roviello; Daniele Marrelli; Alessandro Neri; Daniela Cerretani; Giovanni de Manzoni; Corrado Pedrazzani; Tommaso Cioppa; Giacomo Nastri; Giorgio Giorgi; Enrico Pinto
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

8.  Rare diaphragmatic complications following cytoreductive surgery and HIPEC: report of two cases.

Authors:  Benedikt Lampl; Hubert Leebmann; Max Mayr; Pompiliu Piso
Journal:  Surg Today       Date:  2012-12-07       Impact factor: 2.549

9.  Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival.

Authors:  Patrick L Wagner; Frances Austin; Ugwuji Maduekwe; Arun Mavanur; Lekshmi Ramalingam; Heather L Jones; Matthew P Holtzman; Steven A Ahrendt; Amer H Zureikat; James F Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

10.  Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.

Authors:  Tommaso Cioppa; Marco Vaira; Camilla Bing; Silvia D'Amico; Alessandro Bruscino; Michele De Simone
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.